# Agios Pharmaceuticals, Inc. (AGIO) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/AGIO
## Company Profile
- Ticker: AGIO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology, Rare Disease
## Stock Data
- Close: 31.72 USD
- Market cap: 1576592354.5900002 USD
- Last updated: 2026-08-05
## Business Overview
### Rare Disease Hematology Company
Agios is a commercial-stage biopharmaceutical company focused on rare diseases, with a foundation in hematology. Its current business is anchored by mitapivat, sold as PYRUKYND and AQVESME, while the company expands into additional rare hematology and metabolic disease programs.
### Mitapivat Commercial Expansion
Mitapivat generated $44.7 million in worldwide net revenue in the second quarter of 2026. U.S. revenue was driven by the launch of AQVESME in thalassemia, while ex-U.S. revenue reflected European approval and early demand in Gulf Cooperation Council countries. Mitapivat is now approved for adults with thalassemia in the U.S., Saudi Arabia, United Arab Emirates, and the EU.
### Sickle Cell Disease Opportunity
Agios is pursuing mitapivat in sickle cell disease through the FDA accelerated approval pathway. The FDA granted Priority Review for the supplemental NDA, with a PDUFA date of November 1, 2026, and the company has started the REIGNITE confirmatory Phase 3 trial.
### Pipeline Diversification
The company is broadening beyond mitapivat. It licensed cevidoplenib, an oral SYK inhibitor for immune thrombocytopenia, and plans Phase 3 development after CMC work. AG-236, an siRNA targeting TMPRSS6, is advancing into Phase 2/3 development for polycythemia vera, while AG-181 is in Phase 1b testing for PKU.
## Why The Stock Is Moving

As of Aug 5, 2026, AGIO closed up 0.38% at $31.72. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA PDUFA date for mitapivat in sickle cell disease on November 1, 2026.
- Phase 2 portion initiation for AG-236 in polycythemia vera in the second half of 2026.
- AG-181 Phase 1b data in PKU expected in the second half of 2026.
- Cevidoplenib Phase 3 development in ITP expected to begin in the first half of 2028.

## Recent News
- 2026-07-30 10:30 EST — [Agios Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/AGIO/agios-reports-second-quarter-2026-financial-results-and-provides-business-update-2482094f) — Source: Agios Pharmaceuticals, Inc.
- 2026-07-21 11:00 EST — [Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease](https://biopharmsignal.com/news/AGIO/agios-provides-update-on-phase-2-trial-of-tebapivat-in-sickle-cell-disease-847f0155) — Source: Agios Pharmaceuticals, Inc.
- 2026-07-07 11:00 EST — [U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease](https://biopharmsignal.com/news/AGIO/u-s-fda-grants-priority-review-to-agios-snda-for-mitapivat-in-sickle-cell-diseas-ca03247b) — Source: Agios Pharmaceuticals, Inc.
- 2026-06-29 11:00 EST — [Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET](https://biopharmsignal.com/news/AGIO/agios-to-host-second-quarter-2026-financial-results-conference-call-and-webcast--fc5d305e) — Source: Agios Pharmaceuticals, Inc.
- 2026-06-13 13:00 EST — [Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease](https://biopharmsignal.com/news/AGIO/agios-showcases-rise-up-phase-3-results-at-eha-2026-plenary-session-reinforcing--2ee47a9d) — Source: Agios Pharmaceuticals, Inc.